RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS

Patent metadata

Field	Value
Publication number	US-9738933-B2
Application number	US-201314648306-A
Country	US
Kind code	B2
Filing date	Dec 5, 2013
Priority date	Dec 5, 2012
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.

First claim

What is claimed is:

1. A method for treating a subject with non-del(5q) myelodysplastic syndrome (MDS), comprising
a) measuring erythroid expression levels of Ring Finger Protein 41 (RNF41) in a sample from the subject prior to treatment with lenalidomide (LEN);
b) detecting levels of RNF1 in the subject sample that are reduced compared to a control value established from one or more non-responders to LEN; and
(c) administering to the subject a therapeutically effective dose of LEN, or a functional derivative thereof.

2. The method of claim 1 , wherein the sample is a blood or bone marrow sample.

3. The method of claim 1 , wherein step a) comprises measuring RNF41 protein expression levels in the sample.

4. The method of claim 3 , wherein RNF41 protein expression levels are measured using an immunoassay comprising an antibody that specifically binds RNF41.

5. The method of claim 4 , wherein the immunoassay comprises enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, or flow cytometery.

6. The method of claim 1 , wherein step a) comprises measuring RNF41 gene expression levels in the sample.

7. The method of claim 6 , wherein RNF41 gene expression levels are measured using one or more oligonucleotides that function as primers or probes for detecting RNF41 gene expression levels.

8. The method of claim 1 , wherein the mean levels of RNF41 are reduced by at least 10% compared to a value from a control sample from a known non-responder.

Assignees

• H Lee Moffitt Cancer Ct & Res

Inventors

• List Alan

Classifications

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N2333/9015

  Ligases (6) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/158

  Expression markers · CPC title